Zaid Afawi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zaid Afawi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Christian G. Bouwkamp
Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication- Elena A. Gorobets
Kazan Federal University
1 shared publication - Malik Yousef
Department of Software Engineering, Kinneret Academic College on the Sea of Galilee, Zemach 1513200, Israel
1 shared publication Miar Yousef
Lady Davis Carmel Medical Center, Haifa, Israel
1 shared publication- Naim Abu-Freha
The Institute of Gastroenterology and Hepatology Soroka University Medical Center Beer‐Sheva Israel
1 shared publication Noor Sanalla
Internal Medicine Department, Soroka University Medical Center, Beer-Sheva, Israel
1 shared publication
Latest Publications
- 11 April 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 191, 110179
A machine learning approach to differentiate stage IV from stage I colorectal cancer
- 11 April 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 191, 110179
A machine learning approach to differentiate stage IV from stage I colorectal cancer
- Open Access
- 16 November 2019
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 64 (5)
Glucose Transporter 1 deficiency and associated conditions in children
The article reviews literature devoted to the glucose transporter type I deficiency syndrome (synonyms: GLUT1 deficiency syndrome, de Vivo disease), that is a genetically determined disease caused by pathogenic variants of the SLC2A1 gene. The insufficiency of this protein leads to the disruption of glucose delivery to the brain through the blood-brain barrier. Clinically, the syndrome is manifested by epileptic seizures (mainly as absences or myoclonic seizures), various motor disorders and psychomotor retardation starting from the early age.Early diagnosis (including molecular genetic analysis of the SLC2A1 gene) enables us to start treatment and prevent progression of the symptoms, and to provide the family with genetic consultation on the prognosis and risks for the next generations. Ketogenic diet is an effective treatment option for this pathological condition, it can lead to a regression of the clinical manifestations, especially on the early stage.
- 16 November 2019
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 64 (5)
Open AccessGlucose Transporter 1 deficiency and associated conditions in children
The article reviews literature devoted to the glucose transporter type I deficiency syndrome (synonyms: GLUT1 deficiency syndrome, de Vivo disease), that is a genetically determined disease caused by pathogenic variants of the SLC2A1 gene. The insufficiency of this protein leads to the disruption of glucose delivery to the brain through the blood-brain barrier. Clinically, the syndrome is manifested by epileptic seizures (mainly as absences or myoclonic seizures), various motor disorders and psychomotor retardation starting from the early age.Early diagnosis (including molecular genetic analysis of the SLC2A1 gene) enables us to start treatment and prevent progression of the symptoms, and to provide the family with genetic consultation on the prognosis and risks for the next generations. Ketogenic diet is an effective treatment option for this pathological condition, it can lead to a regression of the clinical manifestations, especially on the early stage.
- 1 January 2019
- Published by Elsevier
- p. 181-202
Clinical Genetic Testing and Counseling in Psychiatry